Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism

Brian J. Willett, Joe Grove, Oscar A MacLean, Craig Wilkie, Nicola Logan, Giuditta De Lorenzo, Wilhelm Furnon, Sam Scott, Maria Manali, Agnieszka Szemiel, Shirin Ashraf, Elen Vink, William Harvey, Chris Davis, Richard Orton, Joseph Hughes, Poppy Holland, Vanessa Silva, David Pascall, Kathryn Puxty, Ana da Silva Filipe, Gonzalo Yebra, Sharif Shaaban, Matthew T. G. Holden, Rute Maria Pinto, Rory Gunson, Kate Templeton, Pablo Murcia, Arvind H. Patel, The COVID-19 DeplOyed VaccinE (DOVE) Cohort Study investigators, The COVID-19 Genomics UK (COG-UK) Consortium, The G2P-UK National Virology Consortium, The Evaluation of Variants Affecting Deployed COVID-19 Vaccines (EVADE) investigators, John Haughney, David L. Robertson, Massimo Palmarini, Surajit Ray, View ORCID ProfileEmma C. Thomson
doi: https://doi.org/10.1101/2022.01.03.21268111
Brian J. Willett
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: emma.thomson@glasgow.ac.uk brian.willett@glasgow.ac.uk
Joe Grove
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oscar A MacLean
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig Wilkie
2School of Mathematics & Statistics, University of Glasgow, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Logan
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuditta De Lorenzo
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wilhelm Furnon
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sam Scott
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Manali
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agnieszka Szemiel
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shirin Ashraf
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elen Vink
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Harvey
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Davis
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Orton
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Hughes
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Poppy Holland
3NHS Greater Glasgow & Clyde, Glasgow, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa Silva
3NHS Greater Glasgow & Clyde, Glasgow, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Pascall
4MRC Biostatistics Unit, University of Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn Puxty
3NHS Greater Glasgow & Clyde, Glasgow, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana da Silva Filipe
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gonzalo Yebra
5Public Health Scotland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharif Shaaban
5Public Health Scotland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew T. G. Holden
5Public Health Scotland
6School of Medicine, University of St Andrews
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rute Maria Pinto
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rory Gunson
3NHS Greater Glasgow & Clyde, Glasgow, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kate Templeton
7NHS Lothian
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pablo Murcia
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arvind H. Patel
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Haughney
3NHS Greater Glasgow & Clyde, Glasgow, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David L. Robertson
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimo Palmarini
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Surajit Ray
2School of Mathematics & Statistics, University of Glasgow, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma C. Thomson
1MRC-University of Glasgow Centre for Virus Research, UK, G61 1QH.
3NHS Greater Glasgow & Clyde, Glasgow, UK
8London School of Hygiene and Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emma C. Thomson
  • For correspondence: emma.thomson@glasgow.ac.uk brian.willett@glasgow.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Vaccination-based exposure to spike protein derived from early SARS-CoV-2 sequences is the key public health strategy against COVID-19. Successive waves of SARS-CoV-2 infections have been characterised by the evolution of highly mutated variants that are more transmissible and that partially evade the adaptive immune response. Omicron is the fifth of these “Variants of Concern” (VOC) and is characterised by a step change in transmission capability, suggesting significant antigenic and biological change. It is characterised by 45 amino acid substitutions, including 30 changes in the spike protein relative to one of the earliest sequences, Wuhan-Hu-1, of which 15 occur in the receptor- binding domain, an area strongly associated with humoral immune evasion. In this study, we demonstrate both markedly decreased neutralisation in serology assays and real-world vaccine effectiveness in recipients of two doses of vaccine, with efficacy partially recovered by a third mRNA booster dose. We also show that immunity from natural infection (without vaccination) is more protective than two doses of vaccine but inferior to three doses. Finally, we demonstrate fundamental changes in the Omicron entry process in vitro, towards TMPRSS2-independent fusion, representing a major shift in the replication properties of SARS-CoV-2. Overall, these findings underlie rapid global transmission and may alter the clinical severity of disease associated with the Omicron variant.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The EVADE study is supported by HDR-UK (E.C.T). COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) [grant code: MC_PC_19027], and Genome Research Limited, operating as the Wellcome Sanger Institute (G.M., R.M.B., D.L.R., E.C.T.). The COVID-19 DeplOyed VaccinE (DOVE) study is funded by the Medical Research Council core award (MCUU1201412) and COG-UK. We acknowledge the support of the G2P-UK National Virology Consortium (MR/W005611/1) funded by the UKRI (M.P.,E.C.T.). A.F., J.H., R.O and D.L.R acknowledge the MRC (MC_UU_12014/12) and DLR the Wellcome Trust (220977/Z/20/Z). W.T.H. is funded by the MRC (MR/R024758/1 and MR/W005611/1). N.L. and B.J.W. were funded by the Biotechnology and Biological Sciences Research Council (BBSRC, BB/R004250/1), G.T. was funded by the Department of Health and Social Care (DHSC, BB/R019843/1). J.G. is supported by a Sir Henry Dale Fellowship from the Wellcome Trust and Royal Society (107653/Z/15/A) and by the Medical Research Council (MC_UU_12014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The North West Central Liverpool Research Ethics Committee/IRB gave ethical approval for the DOVE study (21/NW/0073). Informed written consent was obtained for all participants. In addition, the NHS GG&C SafeHaven gave derogated ethical approval for the use of anonymised population data (GSH/21/IM/001). NHS Caldicott approval was also obtained for the use of anonymised clinical data. Lothian biorepository ethical approval was given for the isolation of virus from clinical samples (reference 10/S1402/33).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵*** Full list of consortium names and affiliations are listed in the appendix

Data Availability

All sequence data are published via GISAID. All data produced in the present study are available upon reasonable request to the authors other than identifying clinical information.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 03, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism
Brian J. Willett, Joe Grove, Oscar A MacLean, Craig Wilkie, Nicola Logan, Giuditta De Lorenzo, Wilhelm Furnon, Sam Scott, Maria Manali, Agnieszka Szemiel, Shirin Ashraf, Elen Vink, William Harvey, Chris Davis, Richard Orton, Joseph Hughes, Poppy Holland, Vanessa Silva, David Pascall, Kathryn Puxty, Ana da Silva Filipe, Gonzalo Yebra, Sharif Shaaban, Matthew T. G. Holden, Rute Maria Pinto, Rory Gunson, Kate Templeton, Pablo Murcia, Arvind H. Patel, The COVID-19 DeplOyed VaccinE (DOVE) Cohort Study investigators, The COVID-19 Genomics UK (COG-UK) Consortium, The G2P-UK National Virology Consortium, The Evaluation of Variants Affecting Deployed COVID-19 Vaccines (EVADE) investigators, John Haughney, David L. Robertson, Massimo Palmarini, Surajit Ray, Emma C. Thomson
medRxiv 2022.01.03.21268111; doi: https://doi.org/10.1101/2022.01.03.21268111
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism
Brian J. Willett, Joe Grove, Oscar A MacLean, Craig Wilkie, Nicola Logan, Giuditta De Lorenzo, Wilhelm Furnon, Sam Scott, Maria Manali, Agnieszka Szemiel, Shirin Ashraf, Elen Vink, William Harvey, Chris Davis, Richard Orton, Joseph Hughes, Poppy Holland, Vanessa Silva, David Pascall, Kathryn Puxty, Ana da Silva Filipe, Gonzalo Yebra, Sharif Shaaban, Matthew T. G. Holden, Rute Maria Pinto, Rory Gunson, Kate Templeton, Pablo Murcia, Arvind H. Patel, The COVID-19 DeplOyed VaccinE (DOVE) Cohort Study investigators, The COVID-19 Genomics UK (COG-UK) Consortium, The G2P-UK National Virology Consortium, The Evaluation of Variants Affecting Deployed COVID-19 Vaccines (EVADE) investigators, John Haughney, David L. Robertson, Massimo Palmarini, Surajit Ray, Emma C. Thomson
medRxiv 2022.01.03.21268111; doi: https://doi.org/10.1101/2022.01.03.21268111

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (240)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1420)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (584)
  • Epidemiology (10297)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2629)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1733)
  • Health Policy (789)
  • Health Systems and Quality Improvement (673)
  • Hematology (266)
  • HIV/AIDS (565)
  • Infectious Diseases (except HIV/AIDS) (12093)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (289)
  • Neurology (2461)
  • Nursing (145)
  • Nutrition (377)
  • Obstetrics and Gynecology (492)
  • Occupational and Environmental Health (568)
  • Oncology (1323)
  • Ophthalmology (401)
  • Orthopedics (146)
  • Otolaryngology (237)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (780)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2397)
  • Public and Global Health (5007)
  • Radiology and Imaging (893)
  • Rehabilitation Medicine and Physical Therapy (528)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (245)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)